查看文章

Primary nonresponse, defined as lack of clinical benefit during the induction phase, occurs in up to 30% of IBD patients treated with infliximab. The mechanisms underlying primary nonresponse have not yet been clearly defined.

To evaluate the association of early (week 2 and week 6) induction infliximab and anti‐infliximab antibody levels with primary nonresponse.

A retrospective observational case‐control study of inflammatory bowel disease patients treated with infliximab and followed at Sheba Medical Center between 2009 and 2016 was performed. Pre‐infusion infliximab and antibodies to infliximab (ATI) levels were measured by our previously described drug‐tolerant ELISA assay.

Thirty‐five primary nonresponders have been identified and matched with 105 primary responders (1:3 ratios). Both week 2 and week 6 infliximab levels were significantly lower among …